Science, Policy, Biotech Thomas Culman Science, Policy, Biotech Thomas Culman

Managing pain without opioids is on the horizon – if we decide it’s worth it

Thanks to the relentless efforts of scientists at Vertex Pharmaceuticals, there will likely soon be a novel non-opioid pain medicine. How insurance plans, including Medicare, decide to cover this drug will make a world of difference to whether we get even better non-opioid options down the road — and whether this progress makes a dent in the ongoing opioid misuse crisis.

Read More
Policy, Biotech Peter Kolchinsky Policy, Biotech Peter Kolchinsky

Egypt and hepatitis C cures — the gift that keeps on giving

In covering how Egypt managed to eradicate hepatitis C, the New York Times rewrites a key bit of history that betrays its misunderstanding of global drug pricing. Egypt’s access to the life-saving Harvoni was a gift from Gilead, not a result of a bare knuckle negotiation. It’s important to understand and explain the increasingly vulnerable system that underpins that gift before bad policy dismantles it.

Read More